Company Analysis: Affimed N.V.

Introduction

Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company headquartered in Mannheim, Germany. The company focuses on harnessing the innate immune system to develop cancer therapies through its proprietary ROCK® platform, which generates Innate Cell Engagers (ICE®) designed to target and kill various tumors.

Corporate Structure

• Employee Count: Affimed employs between 51-200 individuals.
• Industry Focus: The company specializes in biotechnology and immuno-oncology, with a strong emphasis on clinical research and development.
• Management Team: Affimed's management team comprises experienced professionals from the biotechnology and pharmaceutical sectors.

Recent Developments and News

1. Insolvency Proceedings: On May 13, 2025, Affimed announced its decision to file for insolvency proceedings with the local court in Mannheim, Germany. The company cited ongoing fundraising challenges and significant doubts regarding its ability to continue operations as reasons for this decision. The filing has resulted in the suspension of its common shares from trading on Nasdaq, with potential delisting in the future. .

2. NASDAQ Deficiency Notice: On April 21, 2025, Affimed received a notice from Nasdaq indicating that its common shares had closed below the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has until October 13, 2025, to regain compliance or may consider transferring its securities to the Nasdaq Capital Market for an additional compliance period. .

3. ASCO 2025 Annual Meeting: Affimed announced the acceptance of three abstracts for presentation at the ASCO Annual Meeting scheduled for May 30 to June 3, 2025. This includes an oral presentation on the phase 2 LuminICE-203 study involving acimtamig and two poster presentations on AFM24. .

Financial and Strategic Aspects

• Stock Data: As of May 13, 2025, Affimed's stock price is $0.2499, reflecting a price decrease of 63.94%. The trading volume is reported at 251,227 shares.
• Liquidity Concerns: The company has indicated significant liquidity issues, raising concerns about its ability to continue as a going concern. Management has acknowledged the need for additional capital to sustain operations.
• Filing with SEC: Affimed filed a Form 6-K on May 13, 2025, detailing its insolvency proceedings and associated risks, including potential defaults on debt instruments and loss of operational control during the insolvency process. .

Market Position and Industry Context

Affimed operates within the competitive landscape of immuno-oncology, focusing on therapies that leverage the innate immune system. The company's proprietary technology and ongoing clinical trials position it as a participant in the biotechnology sector, although its recent financial challenges and insolvency proceedings may affect its market standing and investor confidence.

TL;DR

Affimed N.V. is currently facing financial challenges, having filed for insolvency on May 13, 2025, due to liquidity issues and inability to raise sufficient capital. The company received a Nasdaq deficiency notice regarding its stock price, which has fallen to $0.2499, down 63.94%. Affimed has until October 13, 2025, to regain compliance with Nasdaq listing requirements. The company will present at the ASCO Annual Meeting from May 30 to June 3, 2025, with three abstracts accepted for presentation.